Alcohol or gut microbiota: who is the guilty? M Meroni, M Longo, P Dongiovanni International journal of molecular sciences 20 (18), 4568, 2019 | 119 | 2019 |
miRNA signature in NAFLD: a turning point for a non-invasive diagnosis P Dongiovanni, M Meroni, M Longo, S Fargion, AL Fracanzani International journal of molecular sciences 19 (12), 3966, 2018 | 103 | 2018 |
The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies M Meroni, M Longo, P Dongiovanni Nutrients 11 (11), 2642, 2019 | 88 | 2019 |
Genetic and epigenetic modifiers of alcoholic liver disease M Meroni, M Longo, R Rametta, P Dongiovanni International journal of molecular sciences 19 (12), 3857, 2018 | 78 | 2018 |
Nutrition and genetics in NAFLD: the perfect binomium M Meroni, M Longo, A Rustichelli, P Dongiovanni International Journal of Molecular Sciences 21 (8), 2986, 2020 | 65 | 2020 |
Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes M Meroni, P Dongiovanni, M Longo, F Carli, G Baselli, R Rametta, ... EBioMedicine 52, 2020 | 61 | 2020 |
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? M Longo, M Meroni, E Paolini, C Macchi, P Dongiovanni Metabolism 117, 154708, 2021 | 48 | 2021 |
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients P Dongiovanni, M Meroni, G Baselli, RM Mancina, M Ruscica, M Longo, ... Journal of lipid research 60 (6), 1144-1153, 2019 | 46 | 2019 |
MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD M Meroni, M Longo, AL Fracanzani, P Dongiovanni EBioMedicine 57, 2020 | 30 | 2020 |
MAFLD in COVID-19 patients: an insidious enemy P Dongiovanni, M Meroni, M Longo, AL Fracanzani Expert Review of Gastroenterology & Hepatology 14 (10), 867-872, 2020 | 29 | 2020 |
TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models M Longo, M Meroni, E Paolini, V Erconi, F Carli, F Fortunato, D Ronchi, ... Cellular and Molecular Gastroenterology and Hepatology 13 (3), 759-788, 2022 | 28 | 2022 |
mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance M Meroni, M Longo, V Erconi, L Valenti, S Gatti, AL Fracanzani, ... Nutrients 11 (11), 2597, 2019 | 27 | 2019 |
Remodeling of mitochondrial plasticity: the key switch from NAFLD/NASH to HCC M Longo, E Paolini, M Meroni, P Dongiovanni International Journal of Molecular Sciences 22 (8), 4173, 2021 | 26 | 2021 |
Genetics is of the essence to face NAFLD M Meroni, M Longo, G Tria, P Dongiovanni Biomedicines 9 (10), 1359, 2021 | 25 | 2021 |
Low lipoprotein (a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease M Meroni, M Longo, R Lombardi, E Paolini, C Macchi, A Corsini, ... Hepatology Communications 6 (3), 535-549, 2022 | 12 | 2022 |
The rs599839 A> G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients M Meroni, M Longo, E Paolini, A Alisi, L Miele, ER De Caro, G Pisano, ... Cancers 13 (8), 1783, 2021 | 12 | 2021 |
Genetics, immunity and nutrition boost the switching from NASH to HCC P Dongiovanni, M Meroni, M Longo, S Fargion, AL Fracanzani Biomedicines 9 (11), 1524, 2021 | 10 | 2021 |
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD P Dongiovanni, M Meroni, S Petta, M Longo, A Alisi, G Soardo, L Valenti, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2020 | 9 | 2020 |
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation N Panera, M Meroni, M Longo, A Crudele, L Valenti, E Bellacchio, L Miele, ... EBioMedicine 65, 2021 | 8 | 2021 |
Genetic and metabolic factors: The perfect combination to treat metabolic associated fatty liver disease M Meroni, M Longo, P Dongiovanni EXPLORATION OF MEDICINE. 1 (4), 218-243, 2020 | 7 | 2020 |